Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
1.410
-0.050 (-3.42%)
Oct 24, 2024, 4:00 PM EDT - Market closed
Atossa Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
Oct '24 Oct 24, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Market Capitalization | 177 | 110 | 67 | 203 | 37 | 14 | |
Market Cap Growth | -6.20% | 64.77% | -66.97% | 445.88% | 158.90% | 148.91% | |
Enterprise Value | 104 | 17 | -50 | 63 | 29 | -0 | |
Last Close Price | 1.46 | 0.88 | 0.53 | 1.60 | 0.95 | 1.57 | |
PE Ratio | - | -3.69 | -2.48 | -9.08 | -0.48 | -0.77 | |
PB Ratio | 2.29 | 1.21 | 0.57 | 1.47 | 1.37 | 1.09 | |
P/FCF Ratio | -8.01 | -5.26 | -3.22 | -12.29 | -3.21 | -1.57 | |
P/OCF Ratio | -8.01 | -5.27 | -3.22 | -12.30 | -3.21 | -1.57 | |
EV/EBITDA Ratio | -2.15 | -0.54 | 1.80 | -3.08 | -1.97 | 0.01 | |
EV/EBIT Ratio | -2.15 | -0.54 | 1.80 | -3.08 | -1.96 | 0.01 | |
EV/FCF Ratio | -3.51 | -0.80 | 2.40 | -3.83 | -2.48 | 0.02 | |
Debt / Equity Ratio | - | - | - | - | 0.00 | 0.00 | |
Debt / FCF Ratio | - | - | - | - | 0.00 | -0.01 | |
Quick Ratio | 13.96 | 16.89 | 20.05 | 43.97 | 2.56 | 10.07 | |
Current Ratio | 14.35 | 17.61 | 21.23 | 45.18 | 2.73 | 10.83 | |
Return on Equity (ROE) | -28.00% | -28.80% | -21.05% | -24.93% | -88.42% | -157.00% | |
Return on Assets (ROA) | -19.68% | -17.85% | -13.07% | -13.93% | -31.85% | -82.34% | |
Return on Capital (ROIC) | -20.65% | -18.77% | -13.52% | -15.52% | -45.20% | -98.05% | |
Earnings Yield | -14.11% | -27.29% | -40.29% | -10.17% | -48.04% | -120.26% | |
FCF Yield | -10.18% | -19.00% | -31.06% | -8.13% | -31.20% | -63.73% | |
Buyback Yield / Dilution | 0.86% | 0.43% | -8.27% | -934.13% | -33.09% | -104.36% | |
Total Shareholder Return | 0.86% | 0.43% | -8.27% | -934.13% | -33.09% | -104.36% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.